Live Breaking News & Updates on Protein Antibodies

Stay updated with breaking news from Protein antibodies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody . ....

Foster City , United States , Israel General , San Francisco , Tel Aviv , Flavius Martin , Compugen Ltd , Gilead Public Affairs , Securities Exchange , Gilead Sciences Inc , Tel Aviv Stock Exchange , Exchange Commission , Rights To Later Stage Development , Terms Of The Partnership , Gilead Sciences , Gilead Will Have Exclusive Rights , Later Stage Development , Protein Antibodies , Treat Various Tumor , Upfront Payment , Near Term Milestone Payment , Total Deal Value , Executive Vice President , Anat Cohen Dayag , Securities Act , Securities Exchange Act ,

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tel Aviv , United States , San Francisco , Foster City , Israel General , Yvonne Naughton , Meaghan Smith , Flavius Martin , Jacquie Ross , Gilead Sciences Inc , Gilead Sciences , Rights To Later Stage Development , Terms Of The Partnership , Exchange Commission , Compugen Ltd , Gilead Public Affairs , Securities Exchange , Tel Aviv Stock Exchange , Gilead Will Have Exclusive Rights , Later Stage Development , Protein Antibodies , Treat Various Tumor Types , Upfront Payment , Near Term Milestone Payment , Total Deal Value , Executive Vice President ,

Compugen : 6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca -December 19, 2023 at 07:24 am EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF. ....

United States , Tel Aviv , Israel General , San Francisco , Foster City , Yvonne Naughton , Jacquie Ross , Meaghan Smith , Flavius Martin , Compugen Ltd Nasdaq , Tel Aviv Stock Exchange , Clinical Immunotherapy Program , Gilead Sciences , Exchange Commission , Compugen Ltd , Corporate Communications , Terms Of The Partnership , Gilead Public Affairs , Commission File Number , Gilead Sciences Inc , Securities Exchange , Company Registration Statement On Form , Rights To Later Stage Development , File Number , Principal Executive Offices , License Agreement ,

COVID-19 immune response strengthens over time

COVID-19 immunity may gather strength with more time between vaccination and infection; people who’ve had the virus benefit even from delayed vaccination. ....

United States , Elissa Wolfson , Marcel Curlin , Oregon Health Science University , Drug Administration , Science Advisory Board , Science University , Clinical Investigation Insight , Covid 19 Immunity , Vaccine Recommendations , Accine Intervals , Natural Infection , Immune Response , Hybrid Immunity , Nhanced Hybrid Immunity , Breakthrough Infections , Vaccine Breakthrough Infections , Mmune Response Maturity , Memory Cells , B Cells , Protein Antibodies , Population Level Immunity , Population Immunity , Herd Immunity , Viral Evolution , Oregon Health Amp Science University ,